Document:

EX-10.3

 Exhibit 10.3 

Confidential 

Lock-Up Agreement 

November 29, 2020 
 Ladies
and Gentlemen: 
 The undersigned (the “Stockholder”) understands that:
(i) SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger and Reorganization, dated as of November 29, 2020
(the “Merger Agreement”), with VIRACTA THERAPEUTICS, INC., a Delaware corporation (the “Company”) and SOL MERGER
SUB, INC., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), pursuant to which at the effective time (the “Effective Time”), Merger Sub will
be merged with and into the Company (the “Merger”) and the separate corporate existence of Merger Sub will cease and the Company will continue as the surviving corporation; and (ii) in connection with the Merger, the
stockholders of the Company will receive shares of common stock, par value $0.0001 per share, of Parent (“Parent Common Stock”). Capitalized terms used but not otherwise defined herein shall have the respective meanings
ascribed to such terms in the Merger Agreement. 
 As a material inducement to the willingness of each of the parties to
enter into the Merger Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Stockholder hereby agrees that the Stockholder will not, subject to the exceptions set forth in this
letter agreement, during the period commencing upon the date hereof and ending on the date that is 180 days after the Effective Time (the “Restricted Period”), (a) offer, pledge, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock or any securities convertible into or
exercisable or exchangeable for Parent Common Stock, including without limitation, Parent Common Stock or such other securities which may be deemed to be beneficially owned by the Stockholder in accordance with the rules and regulations of the U.S.
Securities and Exchange Commission and securities of Parent which may be issued upon exercise of a stock option or warrant (collectively, Shares”), (b) enter into any swap or other agreement that transfers, in whole or in part,
any of the economic consequences of ownership of the Shares, regardless of whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Parent Common Stock or such other securities, in cash or otherwise or
(c) make any demand for or exercise any right with respect to the registration of any shares of Parent Common Stock or any security convertible into or exercisable or exchangeable for Parent Common Stock, in each case other than: 

(i) transfers of Shares as bona fide charitable contributions, gifts or donations, 

(ii) transfers or dispositions of Shares to any trust for the direct or indirect benefit of the Stockholder or the immediate
family of the Stockholder, 
 (iii) transfers or dispositions of Shares by will, other testamentary document or intestate
succession to the legal representative, heir, beneficiary or a member of the immediate family of the Stockholder, 
 (iv)
transfers of Shares to stockholders, direct or indirect affiliates (within the meaning set forth in Rule 405 under the Securities Act), current or former partners (general or limited), members or managers of the Stockholder, as applicable, or to the
estates of any such stockholders, affiliates, partners, members or managers, or to another corporation, partnership, limited liability company or other business entity that controls, is controlled by or is under common control with the Stockholder,

  
 1 

 (v) transfers that occur by operation of law pursuant to a qualified
domestic relations order or in connection with a divorce settlement, 
 (vi) transfers or dispositions not involving a
change in beneficial ownership, 
 (vii) if the Stockholder is a trust, transfers or dispositions to any beneficiary of the
Stockholder or the estate of any such beneficiary; provided that, in each case, the transferee agrees in writing to be bound by the terms and conditions of this letter agreement and either the Stockholder or the transferee provides
Parent with a copy of such agreement promptly upon consummation of any such transfer, 
 (viii) transfers pursuant to a bona
fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Parent’s capital stock involving a change of control of the Parent, provided that in the event that such tender offer, merger,
consolidation or other such transaction is not completed, the Shares shall remain subject to the restrictions contained in this letter agreement, 

provided, that in each case of clauses (i)-(vii), no filing by any party (donor, donee, transferor or transferee) under the
Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than filings made in respect of involuntary transfers or dispositions or a filing on a Form 5 made after
the expiration of the Restricted Period) and any such transfer or distribution shall not involve a disposition for value. For purposes of this letter agreement, “immediate family” shall mean any relationship by blood, marriage or adoption,
not more remote than first cousin. 
 Notwithstanding the restrictions imposed by this letter agreement, the Stockholder may
(a) exercise an option or warrant to purchase Shares (including a net or cashless exercise of such option or warrant provided the Shares are transferred to Parent and not sold on the open market) and provided
further, that the underlying Shares shall continue to be subject to the restrictions on transfer set forth in this letter agreement, (b) transfer Shares to Parent to cover tax withholding obligations of the Stockholder in
connection with any option exercise, (c) establish a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Shares, provided that such plan does not provide for any
transfers of Shares during the Restricted Period and, provided further, that, no filing under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with the
establishment of such a plan, or (d) transfer or dispose of Shares acquired on the open market following the Effective Time. 

Any attempted transfer in violation of this letter agreement will be of no effect and null and void, regardless of whether the
purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this letter agreement, and will not be recorded on the stock transfer books of Parent. In order to ensure compliance with the restrictions
referred to herein, the Stockholder agrees that Parent may issue appropriate “stop transfer” certificates or instructions. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any
certificate(s) or other documents or instruments evidencing ownership of the Shares: 
 THE SHARES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. 

The Stockholder hereby represents and warrants that the Stockholder has full power and authority to enter into this letter
agreement. All authority conferred or agreed to be conferred and any obligations of the Stockholder under this letter agreement will be binding upon the successors, assigns, heirs or personal representatives of the Stockholder. 

In the event that during the Restricted Period any holder of Parent’s securities that is subject to a substantially
similar agreement entered into by such holder, other than the Stockholder, is permitted by Parent to 

  
 2 

 
sell or otherwise transfer or dispose of shares of Parent Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder, the same
percentage of shares of Parent Common Stock held by the Stockholder shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the “Pro-Rata
Release”); provided, however, that such Pro-Rata Release shall not be applied unless and until permission has been granted by Parent to an equity holder or equity
holders to sell or otherwise transfer or dispose of all or a portion of such equity holders’ shares of Parent Common Stock in an aggregate amount in excess of 1% of the number of shares of Parent Common Stock originally subject to a
substantially similar agreement. 
 Upon the release of any Shares from this letter agreement, Parent will cooperate with
the Stockholder to facilitate the timely preparation and delivery of certificates or the establishment of book entry positions at the Parent’s transfer agent representing the Shares without the restrictive legend above and the withdrawal of any
stop transfer instructions at the Parent’s transfer agent. 
 The Stockholder understands that each of Parent and the
Company is relying upon this letter agreement in proceeding toward consummation of the Merger. The Stockholder further understands that this letter agreement is irrevocable and is binding upon the Stockholder’s heirs, legal representatives,
successors and assigns. 
 This letter agreement and any claim, controversy or dispute arising under or related to this
letter agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof. 

The Stockholder understands that if the Merger Agreement is terminated in accordance with its terms, the Stockholder will be
released from all obligations under this letter agreement. 
 This letter agreement may be executed by electronic (i.e.,
PDF) transmission, which is deemed an original. 
 [Signature Page Follows] 

  
 3 

 
							
		 	 Very truly yours,

		
	 Print Name of Stockholder:
	 	  

		
		 	Signature (for individuals):
		
		 	  

		
		 	Signature (for entities):
			
		 	 By:
	 	  

				
		 		 	 Name:
	 	  

				
		 		 	 Title:
	 	  

  
 [SIGNATURE
PAGE TO LOCK-UP AGREEMENT]EX-10.4

 Exhibit 10.4 

SUNESIS PHARMACEUTICALS, INC. 

November [    ], 2020 
 [EMPLOYEE NAME] 

RE:    Exercise Period Extension and Retention Bonus Agreement 

Dear [EMPLOYEE NAME]: 
 As you know, Sunesis Pharmaceuticals,
Inc. (the “Company”) has executed an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), which, if the transactions contemplated thereby are consummated (the
“Acquisition”), will make Viracta Therapeutics, Inc. a wholly-owned subsidiary of the Company. You are receiving this letter because the Company desires to offer to you a retention bonus and extend the post-termination
exercise period associated with options you hold under the Company’s 2011 Equity Incentive Plan (the “Plan”), subject to the terms contained in this letter agreement (this “Retention Agreement”).
This Retention Agreement is conditioned upon, and will become effective as of, the date of the closing of the Acquisition (the “Closing Date”). If the Acquisition is not consummated, this Retention Agreement will have no
effect, will not be binding on the Company or on you, and neither you nor the Company will have any rights or obligations hereunder. 
  

	1.	 Retention Bonus 

In connection with the Acquisition, as an incentive for you to continue to contribute your efforts, talents and services to the Company continuously until the
Closing Date, the Company is pleased to announce you will receive your 2020 target bonus, regardless of actual performance, in an amount equal to $[    ] (the “Retention Bonus”), based on the eligibility
requirements set forth in this Retention Agreement. The Retention Bonus will be paid in a single lump sum, less payroll withholdings and deductions, on the first regularly scheduled payroll date occurring following the later of (i) the
Release Effective Date (as defined below), and (ii) the Closing Date. 
  

	2.	 Option Exercise Period Extension 

As an additional incentive, the Company has adopted an amendment (the “Option Amendment”) which provides that each of your outstanding
options granted under the Plan that are vested and that have an exercise price less than $10 per share (each, an “Eligible Option”) will remain exercisable until the earlier of (i) 12 months after the effective date of your
termination, and (ii) the expiration date of your Eligible Option (the “Extended Exercise Period”). The Option Amendment will contingent on the terms of this Retention Agreement and will become effective as of the
earlier of (a) the Release Effective Date and (b) the Closing Date. Any unexercised options subject to an Eligible Option shall be automatically cancelled at the end of the Extended Exercise Period without any payment. Your Eligible
Options are set forth on Exhibit A, hereto. Each of your options that are not Eligible Options will continue to be governed by the terms of the Plan and your option agreement. 

If any of your Eligible Options are incentive stock options, please note that in order to receive the tax benefits of an incentive stock option, you must hold
the shares for both (i) two years from the date of grant, and (ii) one year from the date of exercise and that, by accepting the Option Amendment, each of your Eligible Options will be treated as if newly granted under the incentive stock
option regulations and will restart the “two years from date of grant” holding period. If you do not accept the Option Amendment, then your Eligible Options will remain subject to their original terms. You should consult your own
personal tax advisor for information regarding the tax treatment of stock option transactions. 
  

	3.	 Outplacement  

As an additional incentive, based on the eligibility requirements set forth in this Retention Agreement, in the event you suffer an Involuntary Termination
Without Cause (as defined in your executive severance benefits agreement) on or prior to the Closing Date, then in addition to any benefits you may be entitled to under a severance benefit agreement with the Company, upon your separation from the
Company, you will receive outplacement services for six months (the “Outplacement Benefit”). 
  

	4.	 Eligibility  

In order to be eligible for the Retention Bonus and the Option Amendment, you must either (i) remain employed by the Company on a full-time basis in good
performance standing continuously until the Closing Date, with your termination to be effective immediately upon the Closing Date, or (ii) suffer an Involuntary Termination Without Cause (as defined in your executive severance benefits
agreement) on or prior to the Closing Date. In order to be eligible for the Outplacement Benefit, you must suffer an Involuntary Termination Without Cause (as defined in your executive severance benefits agreement) on or prior to the Closing Date.
In addition and notwithstanding the foregoing, in order to be eligible for the Retention Bonus, the Option Amendment and the Outplacement Benefit, you must execute and deliver a general release of all known and unknown claims in a release agreement
acceptable to the Company (the “Release”) within no later than forty-five (45) calendar days following the earlier of (a) your Involuntary Termination Without Cause, and (b) the Closing Date, and permit the
Release to become effective and irrevocable in accordance with its terms (the effective date of such release, the “Release Effective Date”). 

[Remainder of page intentionally left blank.] 

	
	Sincerely,
	
	  
 Dayton Misfeldt

	Interim Chief Executive Officer

 ACKNOWLEDGMENT AND ACCEPTANCE 

 

							
	Accepted and Agreed:	  	                        	  		  	
				
		  		  	Date: _______________	  	
	  
 [EMPLOYEE NAME]
	  		  		  	

 EXHIBIT A 

Eligible Options

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]